Challenge

Novo Nordisk wanted to strengthen their dialogue with healthcare professionals by understanding the context in which HPCs work when they treat patients with type 2 diabetes. To get this understanding Novo Nordisk needed insights into which factors determine whether a person develops type 2 diabetes, what are the correlations between these factors and how patients with type 2 diabetes are treated in different parts of the country.

Solution

In close collaboration with Novo Nordisk, we identified a number of demographic variables as well as variables such as income, smoking habits, average life expectancy, BMI + about 30 more. Our skilled data science team developed an analysis tool that makes the many data sources work together enabling Novo Nordisk to see if there are correlations between variables and the development of type 2 diabetes. We can switch on several variables and thus assess the importance of the individual variables for the development of type 2 diabetes (statistically speaking). In addition, all municipal level data was converted to brick-level, to compare with our comprehensive sales data.

The result

By exploring data, Novo Nordisk gained insights, so they now know what to focus on in the dialogue with each individual HCP. By enriching the tool with Signum sales data, we can also shed light on how patients with type 2 diabetes are treated in each brick, i.e. what preference of treatment which is another unique and valuable insight for the dialogue with the HCPs.

With this tool, primarily intended for analysts within Market Access, Novo Nordisk truly breaks down silos as public health, marketing and sales approach each other.